Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dissidents Win Some, Lose Some In Amylin Showdown

This article was originally published in The Pink Sheet Daily

Executive Summary

Shareholder vote rocks the Amylin boat, but only very gently.

You may also be interested in...

Elcelyx Forms Its Own Fund To Lead $20 Million Series C Financing

The money raised will bring the San Diego company’s total to $43 million and will be used to advance its delayed-release metformin, NewMet, through Phase IIb and into a partnership. The cash also will fund an efficacy trial for over-the-counter dietary supplement Lovidia.

Amgen Elects Option On Cardiac Drug, Improving Cytokinetics' Strong Cash Position

Amgen’s decision to take exclusive license to CK-1827452 triggers a $50 million license fee to Cytokinetics.

Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps

Label with expanded language about thyroid cancer risk is expected.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts